Literature DB >> 24075725

Point-of-care derived INR does not reliably detect significant coagulopathy following Australian snakebite.

Kacey M O'Rourke1, Elizabeth Correlje, Cameron L Martin, Jeremy D Robertson, Geoffrey K Isbister.   

Abstract

INTRODUCTION: Point-of-care international normalised ratio (INR) has been suggested as a way to screen for venom-induced consumption coagulopathy following snakebite, but has not been validated for this. This study aimed to assess the diagnostic reliability of point-of-care INR for venom-induced consumption coagulopathy.
METHODS: This was a prospective study of snakebite patients recruited between January 2011 and May 2012 where a point-of-care INR was done and compared to an INR done on a laboratory coagulation analyser, as part of a quality assurance exercise. Data was obtained for each patient, including demographics, information on the snake bite, the point-of-care INR results and any laboratory derived coagulation studies. Snake identification was confirmed by expert identification or venom specific enzyme immunoassay.
RESULTS: There were 15 patients with a median age of 29 years (2 to 68 y) and 13 were male. Four of the 7 patients with venom-induced consumption coagulopathy had an abnormal point-of-care INR (3 false negatives) and 1 of the 7 non-envenomed patients had an abnormal point-of-care INR (1 false positive). The patient with a falsely elevated point-of-care INR was given antivenom prior to formal coagulation studies. The point-of-care INR was also negative in the patient with an anticoagulant coagulopathy.
CONCLUSIONS: The study shows that point-of-care INR testing devices should not be used in suspected snakebite cases in Australia to diagnose venom-induced consumption coagulopathy.
© 2013.

Entities:  

Keywords:  Coagulopathy; Diagnostic tests; Envenomation; INR; IQR; POC; PT; Point-of-care testing; Snakebite; VICC; aPTT; activated partial thromboplastin time; international normalised ratio; interquartile range; point-of-care; prothrombin time; venom induced consumption coagulopathy

Mesh:

Year:  2013        PMID: 24075725     DOI: 10.1016/j.thromres.2013.09.004

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

1.  D-dimer testing for early detection of venom-induced consumption coagulopathy after snakebite in Australia (ASP-29).

Authors:  Geoffrey K Isbister; Tina Noutsos; Shane Jenkins; Katherine Z Isoardi; Jessamine Soderstrom; Nicholas A Buckley
Journal:  Med J Aust       Date:  2022-06-07       Impact factor: 12.776

Review 2.  Diagnosing point-of-care diagnostics for neglected tropical diseases.

Authors:  Mitasha Bharadwaj; Michel Bengtson; Mirte Golverdingen; Loulotte Waling; Cees Dekker
Journal:  PLoS Negl Trop Dis       Date:  2021-06-17

3.  Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation.

Authors:  Matthew Lewin; Stephen Samuel; Janie Merkel; Philip Bickler
Journal:  Toxins (Basel)       Date:  2016-08-25       Impact factor: 4.546

Review 4.  Bedside Coagulation Tests in Diagnosing Venom-Induced Consumption Coagulopathy in Snakebite.

Authors:  Supun Wedasingha; Geoffrey Isbister; Anjana Silva
Journal:  Toxins (Basel)       Date:  2020-09-10       Impact factor: 4.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.